Company: HURA
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0000950170-25-047921
Chunk: 365

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-03-31
Form: 10-K
Item: Item 8
Chunk 365
---
 Stockholders' Equity (Deficit)
     
    $
    19,966,684

    $
    4,361,791

F-5

    Year Ended December 31,

    2024

    2023

    Research and development expenses
     
    $
    13,335,316

    $
    9,402,417

    Acquired in-process research and development ("IPR&D")

    -

    16,217,655

    General and administrative expenses

    4,314,176

    4,144,648

    Operating Loss

    (17,649,492
    )

    (29,764,720
    )

    Other (Expense) Income:

      Employee Retention Tax Credit

    -

    334,443

    Grant income

    57,627

    42,466

    Interest expense

    (4,138,301
    )

    (18,688
    )

    Interest income

    361,632

    89,673

    Change in fair value of derivative liability

    (313,772
    )

    -

    Total Other (Expense) Income

    (4,032,814
    )

    447,894

    Net Loss
     
    $
    (21,682,306
    )
     
    $
    (29,316,826
    )

    Series A Preferred cash dividend

    (2,089
    )

    -

    Deemed dividend on warrant modifications

    (965,177
    )

    -

    Net Loss attributable to common stockholders
     
    $
    (22,649,572
    )
     
    $
    (29,316,826
    )

    Net Loss per share, basic and diluted
     
    $
    (1.21
    )
     
    $
    (2.47
    )

    Weighted-average shares outstanding, basic and diluted

    18,662,690

    11,889,193

F-6

TUHURA BIOSCIENCES, INC AND SUBSIDIARIESConsolidated statements of stockholders’ equity (deficit)For the years ended December 31, 2024, and 2023  

    Total

    Additional

    Accumulated

    Stockholders'

    Preferred Stock

    Common Stock

    Paid in

    Equity